The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 意见
• 07/18/23
0
0
嵌入
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论